Active in Greater China technology and healthcare equity investments, Xiaolei Xiang brings operating and investment experience across growth companies, strategic corporate development, and cross-border capital allocation. He has led deal sourcing and portfolio oversight with a focus on revenue-stage startups, working with founders on go-to-market scaling, commercial partnerships and later-stage exits; prior roles include operating leadership and investment roles in private equity and corporate strategy. Markets view him as a hands-on contributor to capital raises and corporate partnerships with emphasis on operational value creation and governance.
Active in Greater China technology and healthcare equity investments, Xiaolei Xiang brings operating and investment experience across growth companies, strategic corporate development, and cross-border capital allocation. He has led deal sourcing and portfolio oversight with a focus on revenue-stage startups, working with founders on go-to-market scaling, commercial partnerships and later-stage exits; prior roles include operating leadership and investment roles in private equity and corporate strategy. Markets view him as a hands-on contributor to capital raises and corporate partnerships with emphasis on operational value creation and governance.
Focuses on revenue-stage technology and healthcare opportunities in Greater China, prioritizing companies with clear go-to-market traction and scalable commercial models. Investment style is hands-on growth equity: deploying staged capital, structuring founder-aligned governance, and driving operational value through commercial partnerships, business development and exit readiness. Capital allocation favors cross-border winners where corporate strategy and partnership synergies accelerate scale. Risk discipline centers on operational due diligence, metric-driven milestones, and active portfolio oversight to de-risk scaling challenges and preserve optionality for later-stage exits or strategic sales.
Focuses on revenue-stage technology and healthcare opportunities in Greater China, prioritizing companies with clear go-to-market traction and scalable commercial models. Investment style is hands-on growth equity: deploying staged capital, structuring founder-aligned governance, and driving operational value through commercial partnerships, business development and exit readiness. Capital allocation favors cross-border winners where corporate strategy and partnership synergies accelerate scale. Risk discipline centers on operational due diligence, metric-driven milestones, and active portfolio oversight to de-risk scaling challenges and preserve optionality for later-stage exits or strategic sales.
| Trades 81 | Longs Won 36/81 44% | Profit Factor 2.35 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $6.35M |
| Average Win $3.05M | Best Trade (Jul 14) $45.55M | Sharpe Ratio -54.19 |
| Average Loss -$1.04M | Worst Trade (Jul 14) -$15.62M | Z-Score -2.38 (100%) |
| Commissions $0 | Avg. Trade Length 8m 3w 2d | Expectancy $778,184.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 0.09% | 0.75% | 4.69% | 23.57% |
| Consecutive Losing Trades | 346 | 311 | 277 | 242 | 207 | 173 | 138 | 104 | 69 | 35 |